PMGC Holdings Inc (ELAB) — Titan Protect Analysis

ELAB

PMGC Holdings Inc

Healthcare · ·

$1.54

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$8M

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-107.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About PMGC Holdings Inc

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is

https://pmgcholdings.com

Country: United States Employees: 32 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-1.467

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.2134

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.996

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-99.6%

Historical annualised return based on price data

Max Drawdown

-100.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.28

Very low correlation to market moves

52W High

$309.89

100% below the year high

52W Low

$1.62

-5% above the year low

Avg Volume

7,672,978

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-150.06

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

63.12

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-63.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-484.7%

Profit from core operations before interest and tax

Free Cash Flow

$-2,403,837

Negative — the business is spending more than it generates

Revenue (TTM)

$1M

Total revenue over the last 12 months

Net Income

$-11,186,689

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go